Kazuhiko Tsutsumi Selected Research

Kazuhiko Tsutsumi Research Topics

Disease

9	Body Weight (Weight, Body) 11/2021 - 06/2002
9	Type 2 Diabetes Mellitus (MODY) 11/2021 - 08/2007
9	Insulin Resistance 02/2016 - 06/2002
5	Atherosclerosis 09/2006 - 01/2002
4	Hyperlipidemias (Hyperlipidemia) 04/2020 - 06/2002
4	Obesity 01/2015 - 12/2003
3	Fatty Liver 01/2022 - 06/2002
2	Inflammation (Inflammations) 01/2015 - 07/2006
1	Obstructive Sleep Apnea 11/2021
1	Apnea 11/2021
1	Infections 05/2021
1	Dyslipidemias (Dyslipidemia) 01/2021
1	Muscular Diseases (Myopathy) 01/2021
1	Liver Diseases (Liver Disease) 04/2020
1	Arteriosclerosis 08/2007
1	Diabetes Mellitus 07/2006
1	Colonic Neoplasms (Colon Cancer) 02/2005
1	Intestinal Polyps 02/2005
1	Hypertriglyceridemia 01/2003
1	Hyperinsulinism (Hyperinsulinemia) 06/2002
1	Hyperglycemia 06/2002

Drug/Important Bio-Agent (IBA)

12	4- diethoxyphosphorylmethyl- N- (4- bromo- 2- cyanophenyl)benzamideIBA 10/2011 - 01/2002
9	Lipoprotein Lipase (Diacylglycerol Lipase)IBA 10/2011 - 01/2002
8	Glucose (Dextrose)FDA LinkGeneric 05/2021 - 01/2002
7	LipidsIBA 11/2021 - 01/2002
6	Insulin (Novolin)FDA Link 12/2018 - 01/2003
5	Hemoglobins (Hemoglobin)IBA 11/2021 - 12/2018
4	Sodium-Glucose Transporter 2 InhibitorsIBA 11/2021 - 12/2018
4	HDL CholesterolIBA 05/2021 - 09/2006
4	Blood Glucose (Blood Sugar)IBA 05/2021 - 01/2003
4	Triglycerides (Triacylglycerol)IBA 04/2020 - 01/2002
4	CholesterolIBA 09/2006 - 01/2002
3	SymportersIBA 04/2020 - 12/2018
3	SodiumIBA 04/2020 - 12/2018
3	Unsaturated Fatty Acids (Polyunsaturated Fatty Acids)IBA 02/2016 - 08/2007
3	Fatty Acids (Saturated Fatty Acids)IBA 01/2015 - 08/2007
3	Sucrose (Saccharose)IBA 07/2006 - 01/2002
2	Messenger RNA (mRNA)IBA 01/2022 - 02/2005
2	Sodium-Glucose Transport ProteinsIBA 11/2021 - 05/2021
2	Uric Acid (Urate)IBA 11/2021 - 04/2020
2	1,5- anhydro- 1- (5- (4- ethoxybenzyl)- 2- methoxy- 4- methylphenyl)- 1- thioglucitolIBA 05/2021 - 04/2020
2	Dipeptidyl-Peptidase IV InhibitorsIBA 04/2020 - 12/2018
2	Peroxisome Proliferator-Activated Receptors (PPAR)IBA 02/2016 - 02/2005
1	dapagliflozinIBA 01/2022
1	AcidsIBA 01/2022
1	Fibric Acids (Fibrates)IBA 01/2021
1	Phosphotransferases (Kinase)IBA 01/2021
1	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 01/2021
1	(R)-2-(3-((benzoxazol-2-yl-d4 (3- (4- methoxyphenoxy- d7)propyl)amino)methyl)phenoxy) butanoic acidIBA 01/2021
1	CreatinineIBA 01/2021
1	Indicators and Reagents (Reagents)IBA 01/2021
1	Guanosine Triphosphate (GTP)IBA 04/2020
1	Hypoglycemic Agents (Hypoglycemics)IBA 12/2018
1	LigandsIBA 02/2016
1	Hypolipidemic Agents (Antihyperlipidemics)IBA 06/2015
1	Fenofibrate (CiL)FDA LinkGeneric 06/2015
1	PolyphenolsIBA 01/2015
1	Pharmaceutical PreparationsIBA 10/2011
1	Pioglitazone (Actos)FDA Link 10/2011
1	Apolipoprotein A-I (Apolipoprotein A1)IBA 09/2006
1	ATP-Binding Cassette Transporters (ABC Transporters)IBA 09/2006
1	CytokinesIBA 07/2006
1	Uncoupling Protein 3IBA 12/2005
1	PPAR gammaIBA 02/2005
1	PPAR alphaIBA 02/2005
1	Streptozocin (Streptozotocin)FDA Link 02/2004
1	Aspartate Aminotransferases (Aspartate Transaminase)IBA 02/2004
1	Alanine Transaminase (SGPT)IBA 02/2004
1	Epoprostenol (Prostacyclin)FDA LinkGeneric 01/2003
1	Prostaglandins IIBA 01/2003
1	Omega-3 Fatty Acids (Omega 3 Fatty Acids)IBA 01/2003
1	GlycogenIBA 06/2002
1	Liver GlycogenIBA 06/2002

Therapy/Procedure

6	Therapeutics 11/2021 - 10/2011
3	Glycemic Control 04/2020 - 12/2018
1	Continuous Positive Airway Pressure 11/2021